F8
Coagulation factor VIII
As of the edition of 20 October 2026, F8 (coagulation factor VIII, UniProt P00451) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00451
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- Secreted
- Solved structures
- 29
- Disease areas
- Infections; Lungs and airways; Heart and blood vessels; Blood and lymph; Cancer; Digestive system; Nervous system; Pregnancy and women's health
- Registered trials of its drugs
- 22
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Drotrecogin alfa (activated) | Marketed | Phase 4 | Ended 2013 |
| TB-402 | Went quiet | Phase 2 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Undetermined | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| ThromboGenics | Route A |
The other 1 company at F8
In the product2 companies in all; 1 is not named here, and no score is.
See the 2 companies at F8, ranked, with the facts behind eachRequest access. Nothing is shown until you do.